Literature DB >> 27412009

Pathogenetics of the RASopathies.

William E Tidyman1, Katherine A Rauen2.   

Abstract

The RASopathies are defined as a group of medical genetics syndromes that are caused by germ-line mutations in genes that encode components or regulators of the Ras/mitogen-activated protein kinase (MAPK) pathway. Taken together, the RASopathies represent one of the most prevalent groups of malformation syndromes affecting greater than 1 in 1,000 individuals. The Ras/MAPK pathway has been well studied in the context of cancer as it plays essential roles in growth, differentiation, cell cycle, senescence and apoptosis, all of which are also critical to normal development. The consequence of germ-line dysregulation leads to phenotypic alterations of development. RASopathies can be caused by several pathogenetic mechanisms that ultimately impact or alter the normal function and regulation of the MAPK pathway. These pathogenetic mechanisms can include functional alteration of GTPases, Ras GTPase-activating proteins, Ras guanine exchange factors, kinases, scaffolding or adaptor proteins, ubiquitin ligases, phosphatases and pathway inhibitors. Although these mechanisms are diverse, the common underlying biochemical phenotype shared by all the RASopathies is Ras/MAPK pathway activation. This results in the overlapping phenotypic features among these syndromes.
© The Author 2016. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Year:  2016        PMID: 27412009      PMCID: PMC6283265          DOI: 10.1093/hmg/ddw191

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  61 in total

1.  Ras-guanine nucleotide exchange factor sos2 is dispensable for mouse growth and development.

Authors:  L M Esteban; A Fernández-Medarde; E López; K Yienger; C Guerrero; J M Ward; L Tessarollo; E Santos
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

Review 2.  The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions.

Authors:  Seunghee Yoon; Rony Seger
Journal:  Growth Factors       Date:  2006-03       Impact factor: 2.511

3.  Mutation in Sos1 dominantly enhances a weak allele of the EGFR, demonstrating a requirement for Sos1 in EGFR signaling and development.

Authors:  D Z Wang; V E Hammond; H E Abud; I Bertoncello; J W McAvoy; D D Bowtell
Journal:  Genes Dev       Date:  1997-02-01       Impact factor: 11.361

4.  Next-generation sequencing identifies rare variants associated with Noonan syndrome.

Authors:  Peng-Chieh Chen; Jiani Yin; Hui-Wen Yu; Tao Yuan; Minerva Fernandez; Christina K Yung; Quang M Trinh; Vanya D Peltekova; Jeffrey G Reid; Erica Tworog-Dube; Margaret B Morgan; Donna M Muzny; Lincoln Stein; John D McPherson; Amy E Roberts; Richard A Gibbs; Benjamin G Neel; Raju Kucherlapati
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-21       Impact factor: 11.205

5.  External ear anomalies and hearing impairment in Noonan Syndrome.

Authors:  Dorothée C van Trier; Josephine van Nierop; Jos M Th Draaisma; Ineke van der Burgt; Henricus Kunst; Ellen A Croonen; Ronald J C Admiraal
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2015-04-01       Impact factor: 1.675

6.  Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus.

Authors:  D Viskochil; A M Buchberg; G Xu; R M Cawthon; J Stevens; R K Wolff; M Culver; J C Carey; N G Copeland; N A Jenkins
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

7.  Comparative biochemical properties of normal and activated human ras p21 protein.

Authors:  J P McGrath; D J Capon; D V Goeddel; A D Levinson
Journal:  Nature       Date:  1984 Aug 23-29       Impact factor: 49.962

8.  Germline KRAS mutations cause Noonan syndrome.

Authors:  Suzanne Schubbert; Martin Zenker; Sara L Rowe; Silke Böll; Cornelia Klein; Gideon Bollag; Ineke van der Burgt; Luciana Musante; Vera Kalscheuer; Lars-Erik Wehner; Hoa Nguyen; Brian West; Kam Y J Zhang; Erik Sistermans; Anita Rauch; Charlotte M Niemeyer; Kevin Shannon; Christian P Kratz
Journal:  Nat Genet       Date:  2006-02-12       Impact factor: 38.330

9.  The LDL receptor-related protein 1 (LRP1) regulates the PDGF signaling pathway by binding the protein phosphatase SHP-2 and modulating SHP-2- mediated PDGF signaling events.

Authors:  Julie Craig; Irina Mikhailenko; Nathaniel Noyes; Mary Migliorini; Dudley K Strickland
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

10.  Recurrent inactivating RASA2 mutations in melanoma.

Authors:  Rand Arafeh; Nouar Qutob; Rafi Emmanuel; Alona Keren-Paz; Jason Madore; Abdel Elkahloun; James S Wilmott; Jared J Gartner; Antonella Di Pizio; Sabina Winograd-Katz; Sivasish Sindiri; Ron Rotkopf; Ken Dutton-Regester; Peter Johansson; Antonia L Pritchard; Nicola Waddell; Victoria K Hill; Jimmy C Lin; Yael Hevroni; Steven A Rosenberg; Javed Khan; Shifra Ben-Dor; Masha Y Niv; Igor Ulitsky; Graham J Mann; Richard A Scolyer; Nicholas K Hayward; Yardena Samuels
Journal:  Nat Genet       Date:  2015-10-26       Impact factor: 38.330

View more
  45 in total

Review 1.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

2.  Costello syndrome: Clinical phenotype, genotype, and management guidelines.

Authors:  Karen W Gripp; Lindsey A Morse; Marni Axelrad; Kathryn C Chatfield; Aaron Chidekel; William Dobyns; Daniel Doyle; Bronwyn Kerr; Angela E Lin; David D Schwartz; Barbara J Sibbles; Dawn Siegel; Suma P Shankar; David A Stevenson; Mihir M Thacker; K Nicole Weaver; Sue M White; Katherine A Rauen
Journal:  Am J Med Genet A       Date:  2019-06-20       Impact factor: 2.802

3.  RASopathies are associated with a distinct personality profile.

Authors:  Varoona Bizaoui; Jessica Gage; Rita Brar; Katherine A Rauen; Lauren A Weiss
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2018-04-16       Impact factor: 3.568

Review 4.  KRAS Alleles: The Devil Is in the Detail.

Authors:  Kevin M Haigis
Journal:  Trends Cancer       Date:  2017-09-12

5.  De Novo Missense Variants in TRAF7 Cause Developmental Delay, Congenital Anomalies, and Dysmorphic Features.

Authors:  Mari J Tokita; Chun-An Chen; David Chitayat; Ellen Macnamara; Jill A Rosenfeld; Neil Hanchard; Andrea M Lewis; Chester W Brown; Ronit Marom; Yunru Shao; Danica Novacic; Lynne Wolfe; Colleen Wahl; Cynthia J Tifft; Camilo Toro; Jonathan A Bernstein; Caitlin L Hale; Julia Silver; Louanne Hudgins; Amitha Ananth; Andrea Hanson-Kahn; Shirley Shuster; Pilar L Magoulas; Vipulkumar N Patel; Wenmiao Zhu; Stella M Chen; Yanjun Jiang; Pengfei Liu; Christine M Eng; Dominyka Batkovskyte; Alberto di Ronza; Marco Sardiello; Brendan H Lee; Christian P Schaaf; Yaping Yang; Xia Wang
Journal:  Am J Hum Genet       Date:  2018-06-28       Impact factor: 11.025

Review 6.  RAS Proteins and Their Regulators in Human Disease.

Authors:  Dhirendra K Simanshu; Dwight V Nissley; Frank McCormick
Journal:  Cell       Date:  2017-06-29       Impact factor: 41.582

7.  Targeted Genomic Profiling of Acral Melanoma.

Authors:  Iwei Yeh; Eric Jorgenson; Ling Shen; Mengshu Xu; Jeffrey P North; A Hunter Shain; David Reuss; Hong Wu; William A Robinson; Adam Olshen; Andreas von Deimling; Pui-Yan Kwok; Boris C Bastian; Maryam M Asgari
Journal:  J Natl Cancer Inst       Date:  2019-10-01       Impact factor: 13.506

Review 8.  Emerging therapeutic targets for neurofibromatosis type 1.

Authors:  James A Walker; Meena Upadhyaya
Journal:  Expert Opin Ther Targets       Date:  2018-05-07       Impact factor: 6.902

9.  Hematopoietic and neural crest defects in zebrafish shoc2 mutants: a novel vertebrate model for Noonan-like syndrome.

Authors:  HyeIn Jang; Erin Oakley; Marie Forbes-Osborne; Melissa V Kesler; Rebecca Norcross; Ann C Morris; Emilia Galperin
Journal:  Hum Mol Genet       Date:  2019-02-01       Impact factor: 6.150

10.  Oligodendrocyte RasG12V expressed in its endogenous locus disrupts myelin structure through increased MAPK, nitric oxide, and notch signaling.

Authors:  Haley E Titus; Alejandro López-Juárez; Sadiq H Silbak; Tilat A Rizvi; Madeleine Bogard; Nancy Ratner
Journal:  Glia       Date:  2017-08-30       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.